MIRMMirum Pharmaceuticals, Inc.

Nasdaq mirumpharma.com


$ 34.17 $ 1.08 (3.26 %)    

Friday, 28-Jun-2024 15:59:55 EDT
QQQ $ 479.98 $ -2.50 (-0.52 %)
DIA $ 391.11 $ -0.43 (-0.11 %)
SPY $ 544.70 $ -2.15 (-0.39 %)
TLT $ 91.77 $ -1.74 (-1.86 %)
GLD $ 215.03 $ 0.02 (0.01 %)
$ 34.19
$ 33.65
$ 34.14 x 200
$ 34.19 x 200
$ 33.30 - $ 34.44
$ 23.14 - $ 35.56
2,740,885
na
1.6B
$ 0.99
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-08-2024 03-31-2024 10-Q
2 03-15-2024 12-31-2023 10-K
3 11-02-2023 09-30-2023 10-Q
4 08-07-2023 06-30-2023 10-Q
5 05-04-2023 03-31-2023 10-Q
6 03-08-2023 12-31-2022 10-K
7 11-09-2022 09-30-2022 10-Q
8 08-04-2022 06-30-2022 10-Q
9 05-05-2022 03-31-2022 10-Q
10 03-09-2022 12-31-2021 10-K
11 11-15-2021 09-30-2021 10-Q
12 08-05-2021 06-30-2021 10-Q
13 05-06-2021 03-31-2021 10-Q
14 03-09-2021 12-31-2020 10-K
15 11-12-2020 09-30-2020 10-Q
16 08-06-2020 06-30-2020 10-Q
17 05-07-2020 03-31-2020 10-Q
18 03-12-2020 12-31-2019 10-K
19 11-06-2019 09-30-2019 10-Q
20 08-28-2019 06-30-2019 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-reiterates-buy-on-mirum-pharmaceuticals-maintains-66-price-target

HC Wainwright & Co. analyst Ed Arce reiterates Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and maintains $66 price ta...

 mirum-submits-new-drug-application-to-fda-for-chenodiol-for-treatment-of-ctx

Submission based on the positive Phase 3 RESTORE studyMirum holds orphan designation for chenodiol in CTXPotential to have firs...

 stifel-maintains-buy-on-mirum-pharmaceuticals-raises-price-target-to-66

Stifel analyst Dae Gon Ha maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and raises the price target from $48 to $66.

 citigroup-maintains-buy-on-mirum-pharmaceuticals-raises-price-target-to-64

Citigroup analyst David Lebowitz maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and raises the price target from $...

 jp-morgan-maintains-overweight-on-mirum-pharmaceuticals-raises-price-target-to-39

JP Morgan analyst Jessica Fye maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Overweight and raises the price target fr...

 morgan-stanley-maintains-overweight-on-mirum-pharmaceuticals-raises-price-target-to-57

Morgan Stanley analyst Michael Ulz maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Overweight and raises the price targ...

 jmp-securities-maintains-market-outperform-on-mirum-pharmaceuticals-raises-price-target-to-68

JMP Securities analyst Jonathan Wolleben maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Market Outperform and raises t...

 hc-wainwright--co-maintains-buy-on-mirum-pharmaceuticals-raises-price-target-to-66

HC Wainwright & Co. analyst Ed Arce maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and raises the price target...

 stifel-reiterates-buy-on-mirum-pharmaceuticals-maintains-48-price-target

Stifel analyst Dae Gon Ha reiterates Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and maintains $48 price target.

 baird-maintains-outperform-on-mirum-pharmaceuticals-raises-price-target-to-39

Baird analyst Brian Skorney maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Outperform and raises the price target from...

 mirum-pharmaceuticals-highlights-encouraging-data-for-rare-liver-disease-therapy-from-two-mid-stage-studies

Mirum Pharmaceuticals announced promising interim results from Phase 2b studies of volixibat for primary biliary cholangitis an...

 mirums-volixibat-achieves-interim-analyses-in-vantage-pbc-and-vistas-psc-studies-showed-38-point-reduction-from-baseline-and-23-point-placebo-adjusted-reduction-in-primary-endpoint-of-pruritus

- VANTAGE PBC interim analysis shows 3.8 point reduction from baseline and 2.3 point placebo-adjusted (p=0.0026) reduction in p...

 hc-wainwright--co-reiterates-buy-on-mirum-pharmaceuticals-maintains-58-price-target

HC Wainwright & Co. analyst Ed Arce reiterates Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and maintains $58 price ta...

 mirum-pharmaceuticals-presents-long-term-data-from-its-livmarli-studies-in-algs-and-pfic-highlighted-at-the-easl-annual-congress-june-5-8-2024-in-milan-italy

- Data showcases sustained clinical benefit following seven years of LIVMARLI treatment in patients with Alagille syndrome- Lon...

 hc-wainwright--co-reiterates-buy-on-mirum-pharmaceuticals-maintains-58-price-target

HC Wainwright & Co. reiterates Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and maintains $58 price target.

 mirum-pharmaceuticals-gets-positive-chmp-opinion-for-livmarli-oral-solution-for-the-treatment-of-pfic-in-patients-3-months-or-older

Positive opinion from CHMP based on Phase 3 MARCH study with highly statistically significant (p<0.0001) reduction in prurit...